GLP-1 self-dosing mistakes on TikTok: what the risks actually are

What did @caycurr actually say?

The creator, who has been on a GLP-1 medication for over a year, admitted she stopped taking it abruptly without telling her doctor because she was dealing with personal stress and existing nausea. She described gaining weight rapidly, a return of what she calls her "overeating disorder," feeling "ravenous" and unable to stop eating, plus weight gain in her midsection and face, tighter clothes, and worsening mental health. Her core message: talk to your provider before stopping, make a plan, and don't do what she did. She also noted GLP-1s seem to help with inflammation, and that weight regain after stopping is a real and common fear in the GLP-1 community.

Does the science back this up?

Largely, yes. The weight regain picture is well-documented and the return of hunger she describes is biologically expected. The STEP 4 trial (Rubino et al., 2021, New England Journal of Medicine) found that participants who switched from semaglutide to placebo regained two-thirds of their lost weight within one year. A 2022 follow-up analysis confirmed that weight, appetite, and cardiometabolic markers returned toward baseline after discontinuation. The mechanism isn't mysterious: semaglutide suppresses appetite partly by acting on hypothalamic GLP-1 receptors. When the drug leaves your system, those suppressive signals go with it. Her description of hunger returning "like crazy, which I'm used to" is consistent with what researchers observed, not a personal failure. On inflammation, there is emerging evidence, including a 2023 paper by Drucker in Cell Metabolism, that GLP-1 receptor agonists may have anti-inflammatory effects independent of weight loss, though this remains an active research area and not a settled clinical claim.

What did they get wrong (or right)?

She got the main message right: stopping without medical supervision is a bad idea, and the weight and appetite consequences are real. Credit where it's due, that's honest and useful content. Where she's less precise is the framing around inflammation and mental health. She says the medication "helps so much with inflammation" as if it's established fact, when the evidence is still preliminary in humans. The connection she draws between stopping GLP-1s and worsening mental health is more complicated. GLP-1 receptors do exist in brain regions involved in mood regulation, and some early data from Bliddal et al. (2023, The Lancet Regional Health) suggested mood improvements with semaglutide, but causality is not established. Her mental health worsening could just as easily be explained by the personal stress she described, the weight regain itself, or both. She conflates these without separating them, which isn't harmful but isn't precise either. She also doesn't name her "overeating disorder" clearly, which is understandable given platform content moderation, but it means viewers don't get context about binge eating disorder as a diagnosable condition that deserves real clinical attention, not just GLP-1 coverage.

What should you actually know?

If you are considering stopping or pausing a GLP-1 medication, the biology is working against a clean exit if you haven't made structural changes to eating habits and lifestyle. The STEP 1 trial extension data (Wilding et al., 2022, Diabetes, Obesity and Metabolism) showed that behavior change during treatment predicted less severe regain after stopping, which supports her point that "a lot of it depends on the work that you do." That's accurate. A provider can help you taper doses rather than stopping cold, which may smooth the appetite rebound, though there's limited clinical trial data specifically on tapering protocols. If binge eating disorder is part of your history, stopping a GLP-1 medication is a moment where specialist support, not just a telehealth check-in, may be warranted. GLP-1 drugs are being studied as a potential support for binge eating disorder (Goldschmidt et al., 2023, Obesity Reviews), but they are not approved for it, and stopping them without a behavioral health plan in place carries real risk for people with that history.

Bottom line

• Weight regain after stopping GLP-1s is common and biologically predictable, not a personal failure.
• Abrupt discontinuation without a medical plan removes appetite suppression signals immediately.
• GLP-1s and inflammation: plausible, preliminary, not proven in humans at the level she implies.
• Mental health effects of stopping are real but entangled with other variables in her case.
• If you have a history of disordered eating, a GLP-1 pause requires more than a quick provider call.